Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives

Ammar Abdulrahman Jairoun1,2, Sabaa Saleh Al-Hemyari2,3, Faris El-Dahiyat4,5*, Maimona Jairoun6, Moyad Shahwan6,7, Mena Al Ani8, Mustafa Habebr9,10 and Zaheer-Ud-Din Babar11

Abstract

Background: People with weakened immune systems may not develop adequate protection after taking two doses of the mRNA-combined COVID-19 vaccine. The additional dose may improve the level of protection against Covid-19.

Objectives: Current study aimed to evaluate the knowledge, attitude and determinants of third COVID-19 vaccine booster dose acceptance among population in the UAE.

Methods and materials: This is online descriptive cross-sectional community-based study conducted among the students and faculty of Ajman University from 25 August to 20 October 2021. The questionnaire, which was in the English language, encompassed two sections containing 22 items. Section one gathered the demographic details of the respondents, while Section two used 13 questions to evaluate the respondents' knowledge of and attitude to the third COVID-19 vaccine booster dose.

Results: 614 respondents participated in this study. The average knowledge score was 44.6% with a 95% confidence interval (CI) of [41%, 49%]. Better knowledge scores were observed in postgraduates (OR 4.29; 95% CI 2.28–8.11), employees in the healthcare sector (OR 1.62; 95% CI 1.05–2.51), participants who had relatives infected with the Covid-19 (OR 1.46; 95% CI 1.05–2.51), participants who had infected with Covid-19 (OR 2.21; 95% CI 1.43–3.43) and participants who had received first two doses of the COVID-19 vaccine (OR 2.08; 95% CI 1.40–3.11). The average attitude score was 70.2% with a 95% confidence interval (CI) of [69.2%, 71.2%].

Conclusion: Necessary steps should be taken by the government and public health authorities, in line with the local culture, to increase vaccination acceptance and foster positive attitudes towards the vaccine. A suitable approach to this would be to develop an educational framework that could demonstrate the risks of vaccine avoidance or delay to the general population. Moreover, health authorities should pay more attention to the false information being disseminated across the internet, especially social media. Also, healthcare workers should be trained in vaccinology and virology to make sure that they are able to understand important developments in these fields and convey the findings to their patients.
Introduction

Covid-19 infection caused by Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2), resulting in a disease called coronavirus disease 2019 (Covid-19) [1, 2]. In March 2020, the World Health Organization (WHO) announced that it had classified COVID-19 as a pandemic [2]. The virus that causes Covid-19 appears to spread easily between people and scientists will continue to discover more about how it spreads over time, the available data showed that it spreads through close personal contact (within 6 feet, or 2 m) [3]. Additionally, the virus spreads through released respiratory droplets when an infected person coughs, sneezes, breathes, talks, this spray can be inhaled or enter into the mouth, nose, or eyes of a nearby person [4]. However, Covid-19 can sometimes be spread by exposure to small droplets or mists that remain in the air for several minutes or hours. This is called airborne transmission [5]. Signs and symptoms of Covid-19 may appear two to 14 days after exposure [6]. The period after exposure to the virus and before symptoms appear is called the incubation period [7]. Common signs and symptoms may include: fever, cough, tiredness and loss of taste or smell. Other symptoms of the disease include: shortness of breath or difficulty breathing, muscle pain, sore throat, runny nose, headache, chest pain, redness eye (conjunctivitis), nausea, vomiting and diarrhea [6]. Symptoms of Covid-19 can range from mild to severe, as some people may have only a few symptoms, while others have no symptoms at all [8]. Some people may feel worse about a week after they start, such as worsening shortness of breath and pneumonia [9]. The risk of developing severe symptoms of Covid-19 infection increases with age [10]. Also, certain conditions may increase your risk of developing severe symptoms from Covid-19, including: serious heart disease, cancer, chronic obstructive pulmonary disease, having type 1 or type 2 diabetes, obesity, hypertension, smoking, chronic kidney disease, sickle cell disease or thalassemia, pregnancy and asthma [11–13]. The U.S. Food and Drug Administration (FDA) has granted authorization for some COVID-19 vaccines in the United States. FDA has approved many vaccines, to prevent Covid-19 in 16 years and older people [14]. The vaccine can prevent you from infection with COVID-19 or from developing severe illness if you become infected with the virus that causes it. In addition, the COVID-19 vaccine may provide better protection against infection with COVID-19. A recent study showed that unvaccinated people who had previously had Covid-19 were twice as likely to have a recurrence as those who did get vaccinated [15]. The Centers for Disease Control and Prevention (CDC) recommend a booster dose for people age 65 or older, some people who have been fully vaccinated and whose immune response has weakened over time, such as people who had an organ transplant [16, 17]. People with weakened immune systems may not develop adequate protection after taking two doses of the mRNA-combined COVID-19 vaccine. The additional dose may improve the level of protection against Covid-19. The third dose should be given at least 28 days after the second dose of the mRNA vaccine [18].

Due to the rise of vaccine hesitancy, developing safe vaccines and demonstrating their effectiveness is no longer enough to fight a disease. Referring to people's general uncertainty towards vaccines and their unwillingness to take them, vaccine hesitancy has been listed among the most pressing issues facing public health [19], not least in the context of the COVID-19 pandemic.

In a survey of the general population in Saudi Arabia, 64.7% expressed a willingness to take the COVID-19 vaccine [20]. Another recent study systemically reviewing the extant literature on vaccine acceptance in 33 countries revealed a variation in line with income level and geographical region. For example, Jordan (28.4%) and Kuwait (23.6%), among others, had low acceptance, while Poland (56.3%), Italy (53.7%), and Russia (54.9%) showed moderate acceptance. High acceptance was found to be particularly the case in in eastern Asia, including Malaysia (94.3%), Indonesia (93.3%), and China (91.3%). The conclusion may be drawn that there is a need to enhance the willingness to take the COVID-19 in a number of countries, with the aim of achieving global herd immunity and ending the pandemic [21]. Several positive reasons for vaccine willingness have been noted, such as helping one's society and improving the country's health situation, which would strengthen its economy [22, 23]. On the other hand, vaccine hesitancy occurs for reasons such as mistrust or a lack of confidence—either in the government or in the vaccine itself—in addition to absent information, contradicting official recommendations, and vaccine safety and effectiveness issues [24–27]. Fortunately, it seems that vaccine hesitancy is declining as more information on the vaccine's safety and effectiveness becomes available [24]. However, there are still certain factors affecting individuals' decision to take the vaccine that need to be addressed, including sociodemographic factors, such as education level, as well as attitudes, political standpoints, and perceptions of COVID-19 [28–32].

Keywords: Covid-19, Vaccination, Knowledge, Attitude, Vaccine hesitancy, Acceptance
Healthcare workers have been found to have high vaccine hesitancy, despite their crucial role in fighting the pandemic, whether through modeling good health behavior or actually giving the vaccine. Ref. [33], reviewing 35 studies on healthcare workers and vaccine hesitancy, found a wide range of vaccination hesitancy levels globally, ranging between 4.3% and 72%. Healthcare workers’ perceptions and attitudes towards COVID-19 and its vaccines have been found to be particularly salient to their vaccine hesitancy. Meanwhile, healthcare workers’ role, which puts them first in line to receive the vaccine, as well as their task of administering vaccines to the rest of the population, means that the influential factors shaping their attitudes towards the vaccine, e.g., knowledge, urgently need to be investigated [34]. According to a study in the UAE, people with Arabic nationalities were less likely to take a COVID-19 vaccine compared to the rest of the population, while health science students were more likely to get the vaccine than non-health science students. While a vaccine acceptance rate of 56.3% was found among the study participants, they still reported concerns about unforeseen problems (65.5%) and unforeseen side effects (35.1%) as well as general mistrust (47.3%). The study also found that the participants’ knowledge of COVID-19 varied significantly [35]. Despite the plentiful vaccination opportunities in the UAE, the novelty of the vaccines themselves is highlighting the issues of vaccine acceptance in the country. Furthermore, there is currently a gap regarding knowledge, perceptions and attitudes towards the COVID-19 vaccine among the general population. To address this gap, this novel work examines the knowledge of and attitude towards the COVID-19 vaccine in the UAE, specifically the willingness to receive the third COVID-19 booster dose.

Materials and methods

Study design and setting

This descriptive, cross-sectional analytical study was performed on the community of the faculty and students at Ajman University (AU). The aim was to evaluate their knowledge of and attitude towards receiving a third COVID-19 vaccine dose (hereafter, COVID-19 vaccine booster). Potential respondents were sent an online link via email, and the data collection period was from 25 August to 20 October 2021.

Study participants (inclusion and exclusion criteria)

The target population comprised the students and faculty of AU, including UAE nationals as well as resident non-nationals. The following were used as inclusion criteria: (1) aged 18 years and above and (2) willing to participate in the study.

Questionnaire design

We performed a pilot study in AU towards the end of August 2021 as no work has thus far examined this topic in the context of the UAE. Previous studies exploring knowledge of and attitude towards the COVID-19 vaccine [36–38] were drawn upon to develop the pilot questionnaire. Subsequently, we constructed a self-administered questionnaire based on pre-existing surveys; hereby, all key points of the subject under study were incorporated and the questionnaire was tailored to fit the UAE context. Experts in the subject were asked to review and evaluate the design, content, and relevance of the questionnaire as well as assess its comprehensibility and readability. Three lecturers in pharmacy at AU were then asked to validate the questionnaire, which was consequently modified slightly based on their feedback. The pilot study was then performed on 55 participants using the designed survey before it was fully implemented on the study population.

The questionnaire’s quantitative content validity was estimated by calculating Lawshe’s content validity ratio (CVR) [39] for each item. All items that scored at least 0.78 were considered acceptable; those not achieving the threshold value of 0.78 were removed from the final questionnaire [39]. Next, the mean CVR value of the retained items was calculated to obtain the content-validity index (CVI). The CVI of 0.85 indicated that the questionnaire’s final validity is acceptable [40]. The reliability of the survey was assured through the modifications based on the results from the abovementioned pilot study. Furthermore, as the pilot study raised no issues with the survey instrument, it was used in the principal study, with the abovementioned minor modifications. The pilot study participants were not included in the final analysis. The reliability of the questionnaire was further ensured by calculating Cronbach’s $\alpha$; the $\alpha$-value of 0.75 demonstrated that the internal consistency is acceptable.

The questionnaire was in English and incorporated 22 items in two sections. The items in section one collected the demographic details of the respondents, such as age, sex, employment status and level of education. The 13 items in section two aimed to capture the respondents’ knowledge of and attitude towards the COVID-19 vaccine booster.

Questionnaire scoring

The respondents’ knowledge of the COVID-19 vaccine booster was measured using one item, namely the question “Do you know about the third COVID-19 vaccine booster dose?” Possible answers for this item were “yes” (scoring “1”) and “no” or “don’t know” (both scoring “0”). The remaining 12 items assessed the respondents’
attitudes towards the COVID-19 vaccine booster using a 5-point Likert scale (0 = “strongly disagree”, 1 = “disagree”, 2 = “neutral”, 3 = “agree” and 4 = “strongly agree”). The grading of the 12 items was achieved by summing the raw Likert-scale scores for each respondent. Based on this, a percentage between 0 and 100% was calculated for each respondent, reflecting their general attitude towards the COVID-19 vaccine booster.

Sample size and sampling technique
As highlighted above, a pilot study was used to estimate a suitable sample size for the final survey. Hereby, the pilot questionnaire was sent via email to the target population, i.e., the students and faculty at AU (n = 100); 55 responses were received, giving a response rate of 55%. The calculation of the sample size for the final survey was based on the pilot respondents’ answers to the question “Do you know about the third COVID-19 vaccine booster dose?”, to which around 50% responded “yes”. The selected alpha level of 5% meant a confidence interval (CI) of 95%. The precision (D) of the 95% CI was set to 5%, giving a maximum width of 10% for the 95% CI. Thus, assuming a non-response rate of 40%, a sample size of 640 participants was considered to be suitable. Potential respondents were contacted with the assistance of the Admission and Registration Department at AU, which provided an Excel spreadsheet listing the names, colleges, study years, and email addresses of the students and faculty at AU. Simple random sampling based on the identification (ID) number was used to select potential respondents. Thereafter, the pre-selected respondents were stratified according to their department and college.

Questionnaire administration
The self-administered questionnaire was sent to the randomly selected potential respondents from AU via an online link sent to their emails. On the questionnaire itself, the first page clarified the study’s nature and purpose. Respondents were considered to have consented if they proceeded to the next page. Non-respondents were sent reminder emails every month, and all respondents who completed the study received a thank-you message in an email. No incentives of any kind were offered to the respondents in return for their completing the survey.

Ethical considerations
The Institutional Ethical Review Committee of AU approved this study. All individuals who participated in the survey did so voluntarily. The study purpose was outlined on the cover page of the questionnaire, and respondents’ continuing to the subsequent page were assumed to have given their consent. Respondents’ identities were not recorded in any way, and they were assured of their confidentiality.

Statistical analysis
The statistical analysis was performed via the Statistical Package for the Social Sciences software version 24 (SPSS; IBM Corp., Armonk, NY, USA). Percentage and frequency were used to present the qualitative variables, while the quantitative variables were presented as mean ± standard deviation (SD). The correlations between knowledge of the COVID-19 vaccine booster and the demographic factors were assessed using a Chi-square test. Differences across groups in the quantitative variables were evaluated using unpaired Student’s t-tests, non-parametric versions, and one-way ANOVA. To investigate the factors affecting respondents’ attitude and willing to get the third COVID-19 booster dose, the median score was calculated by categorize the attitude score into dichotomous/binary outcome. In doing so, 34 was calculated as the median score. This dichotomous outcome variable mentioned above was then used in logistic regression models. Variable selection and model building were achieved using the stepwise method. Statistical significance was assumed for p-values below 0.05.

Results
Demographic and baseline characteristics
The demographic factors of the participants are presented in Table 1. A total of 614 respondents participated in this study. Among the total, 69.1% (n = 424) were female and 30.9% (n = 190) male. The age of the participant was detailed as follows: 191 (31.1%) aged 18–22, 236 (38.4%) aged 23–26, 131 (21.3%) aged 27–30, 30 (4.9%) aged 31–36 and 26 (4.2%) aged ≥ 37. Of the total, 22.1% were Emirati, 22.1% were African, 19.7% were Western, 28% were Asian and 8% were Arabic. The educational levels reported were 118 (19.2%) had primary school/elementary, 195 (31.8%) had secondary education, 162 (26.4%) had diploma, 66 (10.7%) were university degree holders and 73 (11.9%) were postgraduates. Among the total subjects, 24.3% (n = 149) were students, 19.5% (n = 120) were unemployed, 26.5% (n = 163) were employee in health sector and 29.6% (n = 182) were employee in non-health sector. Of the total participants, 11.7% have chronic diseases, 37.5% have relatives who infected with the Covid-19, 16.3% have infected with Covid-19, 77% have received first two doses of the COVID-19 vaccine and 10.3% have admitted to hospital due to Covid-19 symptoms.

Participant’s knowledge about third COVID-19 vaccine booster dose
The average knowledge score was 44.6% with a 95% confidence interval (CI) of [41%, 49%]. The knowledge
The average attitude score was 70.2% with a 95% confidence interval (CI) of [69.2%, 71.2%]. The attitude towards third COVID-19 vaccine booster dose was evaluated by asking the participants 12 questions.

Table 3 shows the attitude about third COVID-19 vaccine booster dose according to demographics. Among the studied variables, the univariate analysis revealed that gender \( (P=0.002) \), nationality \( (P=0.01) \), education \( (P=0.001) \), Employment status \( (P=0.001) \), having chronic diseases \( (P=0.001) \), having relatives infected with the Covid-19 \( (P<0.001) \), being infected with Covid-19 \( (P<0.001) \), received first two doses of the COVID-19 vaccine \( (P<0.001) \) and being admitted to hospital due to COVID-19 symptoms.

**Table 1** Demographic characteristics of study participants \( (n=614) \)

| Demographic Groups                          | Frequency | Percentage (%) |
|--------------------------------------------|-----------|----------------|
| Gender                                     |           |                |
| Male                                       | 190       | 30.9           |
| Female                                     | 424       | 69.1           |
| Age                                        |           |                |
| 18–22                                      | 191       | 31.1           |
| 23–26                                      | 236       | 38.4           |
| 27–30                                      | 131       | 21.3           |
| 31–36                                      | 30        | 4.9            |
| ≥ 37                                       | 26        | 4.2            |
| Nationality                                |           |                |
| Emirati                                    | 136       | 22.1           |
| African                                    | 136       | 22.1           |
| Western                                    | 121       | 19.7           |
| Asian                                      | 172       | 28             |
| Arabic                                     | 49        | 8              |
| Education                                  |           |                |
| Primary school/elementary                  | 118       | 19.2           |
| Secondary education                        | 195       | 31.8           |
| Diploma                                    | 162       | 26.4           |
| University degree                          | 66        | 10.7           |
| Post-graduate degree                       | 73        | 11.9           |
| Employment                                 |           |                |
| Student                                    | 149       | 24.3           |
| Unemployed                                 | 120       | 19.5           |
| Employee in health sector                  | 163       | 26.5           |
| Employee in non-health sector              | 182       | 29.6           |
| Do you have any chronic diseases           |           |                |
| Yes                                        | 72        | 11.7           |
| No                                         | 542       | 88.3           |
| Do you have any of your relatives infected with the Covid-19 | | |
| Yes                                        | 230       | 37.5           |
| No                                         | 384       | 62.5           |
| Have you ever infected with Covid-19       |           |                |
| Yes                                        | 100       | 16.3           |
| No                                         | 514       | 83.7           |
| Have you received first two doses of the COVID-19 vaccine | | |
| Yes                                        | 473       | 77             |
| No                                         | 141       | 23             |
| Have you admitted to hospital due to COVID-19 symptoms | | |
| Yes                                        | 63        | 10.3           |
| No                                         | 551       | 89.7           |
COVID-19 symptoms ($P<0.001$) were associated with the attitude towards third COVID-19 vaccine booster dose.

Table 4 shows the results of each questions related to the attitude towards third COVID-19 vaccine booster dose,

Factors influencing the attitude towards third COVID-19 vaccine booster dose

Table 5 displays the of multivariate regression model applied to demographic factors. To select the set of the factors that jointly influence the attitude towards third COVID-19 vaccine booster dose. The results of this procedure showed that better attitude towards third COVID-19 vaccine booster dose were observed in unemployed participants (OR 2.47; 95% CI 2.14–2.86), employee in non-health sector (OR 2.05; 95% CI 1.89–2.23), employee in health sector (OR 1.61; 95% CI 1.49–1.74), participants who had relatives infected with the Covid-19 (OR 1.18; 95% CI 1.05–1.32), those who had infected with Covid-19 (OR 1.25; 95% CI 1.08–1.44), those who received first two doses of the COVID-19 vaccine (OR 1.08; 95% CI 1.02–1.15) and those who had admitted to hospital due to COVID-19 symptoms (OR 2.25; 95% CI 1.84–2.74).
Discussion
The COVID-19 vaccines have been proven to be safe and effective against the disease, and governments across the world have been putting in efforts to relay this information to their populations. Nonetheless, there remain barriers to the public’s willingness to receive the vaccine. To effectively fight against the pandemic, it is necessary to stop the transmission of the virus through herd immunity, which requires a vaccination rate of at least 82% and, hence, strong willingness to vaccinate and low vaccine hesitancy [41]. This shows the importance of determining which factors influence individuals’ vaccine hesitancy and acceptance, which will allow important policy changes to be made and enable public health authorities to develop conceptual frameworks and campaigns that can educate the general population, raising their awareness of the importance of taking the vaccine [42]. As yet, there has been an absence of published evidence on the UAE population’s knowledge, perceptions and attitudes towards the booster dose.

We found that only 44.6% of the participants knew about the booster dose, meaning that more than half of the participants had a low knowledge level on this issue. A substantial body of prior research has established a similar lack of knowledge about COVID-19 vaccines [35, 43–45]. In the present study, this lack of knowledge may be linked to the lack of information dissemination.

Table 3  Participants attitude about the third COVID-19 vaccine booster dose according to demographic variables

| Demographic | Groups | Participants attitude | Mean ± SD | Median | P-value |
|-------------|--------|-----------------------|----------|--------|---------|
| Gender      | Male   | 69.24 ± 0.895         | 70.86    | 0.207  |
|             | Female | 70.60 ± 0.599         | 70.81    |        |
| Age         | 18–22  | 70.91 ± 0.891         | 70.44    | 0.138  |
|             | 23–26  | 69.67 ± 0.801         | 70.34    |        |
|             | 27–30  | 68.66 ± 1.075         | 70.81    |        |
|             | 31–36  | 73.82 ± 2.247         | 79.2     |        |
|             | ≥ 37   | 72.91 ± 2.414         | 70.88    |        |
| Nationality | Emirati| 71.83 ± 1.043         | 70.80    | 0.01*  |
|             | African| 67.91 ± 1.043         | 68.7     |        |
|             | Western| 67.27 ± 1.106         | 67.5     |        |
|             | Asian  | 71.67 ± 0.928         | 71.8     |        |
|             | Arabic | 73.89 ± 1.738         | 75       |        |
| Education   | Primary school/elementary | 72.08 ± 1.024 | 71.8 | 0.001* |
|             | Secondary education    | 69.70 ± 0.797 | 70.87 |        |
|             | Diploma             | 65.98 ± 0.874 | 68.8  |        |
|             | University degree    | 64.17 ± 1.369 | 70.8  |        |
|             | Post-graduate degree | 83.13 ± 1.302 | 85.4  |        |
| Employment  | Student             | 53.93 ± 0.458 | 56.2  | 0.001* |
|             | Unemployed          | 66.71 ± 0.511 | 66.6  |        |
|             | Employee in non-health sector | 72.69 ± 0.438 | 72.9 |        |
|             | Employee in health sector | 83.51 ± 0.415 | 81.3 |        |
| Do you have any chronic diseases | Yes | 60.59 ± 1.395 | 60.4  | 0.001* |
|             | No                 | 71.45 ± 0.509 | 70.8  |        |
| Do you have any of your relatives who infected with the Covid-19 | Yes | 81.73 ± 0.560 | 79.2  | <0.001* |
|             | No                 | 63.26 ± 0.434 | 66.7  |        |
| Have you ever infected with Covid-19 | Yes | 88.00 ± 0.951 | 85.4  | <0.001* |
|             | No                 | 66.71 ± 0.420 | 68.7  |        |
| Have you received first two doses of the COVID-19 vaccine | Yes | 71.92 ± 0.548 | 70.83 | <0.001* |
|             | No                 | 64.34 ± 1.004 | 66.6  |        |
| Have you admitted to hospital due to COVID-19 symptoms | Yes | 91.53 ± 1.261 | 89.6  | <0.001* |
|             | No                 | 67.74 ± 0.426 | 70.8  |        |

*P-values less than 0.05 were considered statistically significant, P-values obtained from the Kruskal–Wallis and Mann–Whitney U tests
Table 4  Participants’ attitude about the third COVID‑19 vaccine booster dose

| Attitude items                                                                 | Strongly disagree | disagree | Neutral | agree | Strongly agree |
|--------------------------------------------------------------------------------|-------------------|----------|---------|-------|----------------|
|                                                                                | $F$ | %   | $F$ | %   | $F$ | %   | $F$ | %   | $F$ | %   |
| Third vaccine dose (COVID‑19 vaccine booster) help increase your immunity against the virus | 2  | 0.3 | 19 | 3.1 | 75 | 12.2 | 165 | 26.9 | 353 | 57.5 |
| Is it very dangerous for health using third dose vaccine (COVID‑19 vaccine booster)? (reverse scored) | 181 | 29.5 | 204 | 33.2 | 124 | 20.2 | 60 | 9.8 | 45 | 7.3 |
| Third vaccine dose (COVID‑19 vaccine booster) increase allergic reactions. (reverse scored) | 118 | 19.2 | 195 | 31.8 | 162 | 26.4 | 66 | 10.7 | 73 | 11.9 |
| Third vaccine dose (COVID‑19 vaccine booster) increase autoimmune diseases. (reverse scored) | 65 | 10.6 | 162 | 26.4 | 161 | 26.2 | 138 | 22.5 | 88 | 14.3 |
| The newly third vaccine dose (COVID‑19 vaccine booster) is safe and effective | 2  | 0.3 | 17 | 2.8 | 77 | 12.5 | 198 | 32.2 | 320 | 52.1 |
| The third vaccine dose (COVID‑19 vaccine booster) is essential for UAE | 9  | 1.5 | 30 | 4.9 | 111 | 18.1 | 189 | 30.8 | 275 | 44.8 |
| I will encourage my family, friends and relatives to get the third vaccine dose (COVID‑19 vaccine booster) | 9  | 1.5 | 23 | 3.7 | 71 | 11.6 | 181 | 29.5 | 330 | 53.7 |
| I will take third vaccine dose (COVID‑19 vaccine booster) without any hesitation, if it is available in my country | 6  | 1.0 | 34 | 5.5 | 52 | 8.5 | 111 | 18.1 | 411 | 66.9 |
| It is not possible to reduce the prevalence of COVID‑19 without a third vaccine dose (COVID‑19 vaccine booster) | 8  | 1.3 | 31 | 5.0 | 124 | 20.2 | 168 | 27.4 | 283 | 46.1 |
| I worry about serious unknown long-term effects of the third vaccine dose (COVID‑19 vaccine booster) in the future | 31  | 5.0 | 103 | 16.8 | 198 | 32.2 | 152 | 24.8 | 130 | 21.2 |
| I believe that third vaccine dose (COVID‑19 vaccine booster) make a lot of money for pharmaceutical companies (reverse scored) | 11  | 1.8 | 47 | 7.7 | 149 | 24.3 | 233 | 37.9 | 174 | 28.3 |
| I believe that first two doses of the COVID‑19 vaccine gives the safest protection (reverse scored) | 29  | 4.7 | 97 | 15.8 | 172 | 28.0 | 199 | 32.4 | 117 | 19.1 |

*F*, frequency; %, percentage
by the government among the public on the importance of taking the vaccine, particularly the booster dose. Meanwhile, the severity of COVID-19, including its mortality rates, may have been underreported or incorrectly transmitted, thereby mitigating the urgency to get the vaccine and highlighting the questions of its safety [46], while the UAE population may be more hesitant to inform themselves about the disease or its vaccines. This underlines the need to give the members of the community access to information on the vaccines that is trusted and grounded in solid evidence. When designing vaccination education campaigns, policymakers should seek to enhance the public’s trust in the vaccines and eliminate the social and financial barriers to vaccination, while aiming to address the public health issues underlying vaccine hesitancy [43–45].

This study found that participants with a higher education level, with a prior history of COVID-19 infection, and a previous experience of having taken the vaccine all demonstrated more knowledge of the booster dose. This is in line with the findings of prior research [47–50]. Similarly, research in China [51] and Hong Kong [48] has revealed that individuals who had already taken the influenza vaccine showed a higher willingness to take the COVID-19 vaccine. This is likely to be due to having had a prior positive experiences of receiving a vaccine.

Overall, 70.2% of the study’s participants expressed that they would receive the booster dose. In comparison, the literature has found that vaccine hesitancy rates range widely across populations and countries. For example, Lazarus et al., as part of a global survey, identified vaccine acceptance rates between below 55% (Russia) and 90% (China) [52]. Similarly, Sallam et al. [53], in a literature review, found substantial variation in vaccine acceptance rates among adults, reaching a high of 97% in Ecuador and lows of 23.6% in Kuwait and 28.4% [23]. Research in the context of sub-Saharan Africa indicated 51% vaccine acceptance, while 67% was found for Saudi Arabia.

### Table 5 Multivariate analysis of factors associated with the attitude about third COVID-19 vaccine booster dose

| Demographic | OR   | 95% CI   | P-value |
|-------------|------|----------|---------|
| **Gender**  |      |          |         |
| Male        | I    |          |         |
| Female      | 0.990| 0.934    | 1.050   | 0.743  |
| **Age**     |      |          |         |
| 18–22       | 1.024| 0.881    | 1.190   | 0.760  |
| 23–26       | 1.028| 0.884    | 1.194   | 0.723  |
| 27–30       | 0.998| 0.856    | 1.162   | 0.975  |
| 31–36       | 0.926| 0.764    | 1.121   | 0.431  |
| ≥ 37        | I    |          |         |
| **Nationality** |    |          |         |
| Emirati     | 1.032| 0.905    | 1.178   | 0.636  |
| African     | 1.020| 0.901    | 1.155   | 0.752  |
| Western     | 0.929| 0.823    | 1.050   | 0.239  |
| Asian       | 0.999| 0.894    | 1.118   | 0.991  |
| Arabic      | I    |          |         |
| **Education** |   |          |         |
| Primary school/elementary | 0.933| 0.820    | 1.062   | 0.295  |
| Secondary education | 0.905| 0.798    | 1.026   | 0.120  |
| Diploma     | 0.892| 0.787    | 1.011   | 0.074  |
| University degree | 0.888| 0.775    | 1.019   | 0.091  |
| Post-graduate degree | I |          |         |
| **Employment** |   |          |         |
| Student     | I    |          |         |
| Unemployed  | 2.473| 2.138    | 2.860   | <0.001*|
| Employee in non-health sector | 2.052| 1.891    | 2.227   | <0.001*|
| Employee in health sector   | 1.611| 1.489    | 1.743   | <0.001*|
| Have any chronic diseases | 0.876| 0.801    | 0.959   | 0.004*|
| Have relatives who infected with the Covid-19 | 1.183| 1.057    | 1.323   | 0.003*|
| Have infected with Covid-19 | 1.246| 1.079    | 1.440   | 0.002*|
| Received first two doses of the COVID-19 vaccine | 1.080| 1.015    | 1.148   | 0.015*|
| Admitted to hospital due to COVID-19 symptoms | 2.249| 1.843    | 2.744   | <0.001*|

*P-values less than 0.05 were considered statistically significant, OR, odds ratio; CI, confidence interval
Finally, Sallam, performing a systemic review, further found vaccine acceptance rates ranging from 27.7% (Congo) to 78.1% (Israel) [54, 55]. The findings for vaccine acceptance among healthcare workers are similar, with substantial variation seen among health science students globally and increased vaccine hesitancy levels in middle- and low-income nations [56, 57].

Recent research in the UAE found that the vaccine acceptance rate was influenced by concerns about unforeseen problems (65.5%), unforeseen impacts (35.1%) and general mistrust (47.3%) [35]. These concerns tended to be linked to the potential side effects of the vaccine as well as the limited availability of trial data assessing its benefits. This finding highlights the need to implement stronger and more effective health education efforts that prioritize a wide range of sociodemographic categories, with the ultimate aim of enhancing the uptake of COVID-19 vaccination, both in the UAE and globally. More information on the vaccines’ side effects and effectiveness would be of great benefit as the research has demonstrated that increased knowledge leads to reduced vaccine hesitancy rates in the long term [32, 58, 59].

A suitable way to achieve this is by strengthening public health education and employing vaccine promoters, such as healthcare workers, to increase the public’s willingness to take the vaccine [60–62].

The findings of this study reveal that individuals’ attitudes towards and willingness to take the booster dose are influenced by a significant number of sociodemographic factors. As a result, we expect that our results will be able to inform future campaigns aiming to foster awareness of health in general and of COVID-19 vaccination in particular.

We found that participants who had a higher education and who had already received both COVID-19 vaccine doses early on were more positively inclined towards COVID-19 vaccination in general and were more willing to take the booster dose. This is consistent with the previous research [31, 38, 48, 49, 51, 63]. For example, a study in Saudi Arabia found that individuals working in the public sector and who had at least a postgraduate degree were more willing to take the COVID-19 vaccine [20].

Furthermore, those participants in our study who had chronic health issues were significantly more likely to be amenable to the booster dose. This contradicts a previous finding that revealed that participants who have chronic diseases are significantly less likely to accept the booster dose than healthy individuals [45]. COVID-19 patients with underlying conditions, such as hypertension, cancer, cardiovascular disease, congestive heart failure, diabetes, and chronic kidney disease, have a significantly higher risk of mortality upon contracting the disease [64], making it crucial for this population to receive the vaccine as soon as possible. As a result, they should be prioritized, and more efforts must be made to raise their awareness of the severity and implications of COVID-19 and how the vaccine can mitigate these.

Among the healthcare workers surveyed in this study, 83.5% expressed that they intended to be vaccinated and 16.5% explicitly stated they would not take the vaccine. A previous study in South and Southeast Asia found high vaccine acceptance rates (at least 95%) in that region, with healthcare workers showing a high willingness to receive the vaccine [65]. This was attributed to their perception of the severity of COVID-19, the safety of the vaccines, the lack of financial constraints, low vaccination stigmatization, and a high level of trust in the public health authorities [65]. Meanwhile, vaccine acceptance was previously found to be in 76.63% in China [66] and 76.10% in Vietnam [67], which is somewhat below the rate found in this study. The conclusion could be drawn that these high rates were due to the participants’ good knowledge of the disease’s severity, trust in the effectiveness and safety of the vaccines, and the fact that the study took place earlier on in the pandemic than our study. A study in Iraq found a lower rate of vaccine acceptance (61.7%) [68], although this was a higher rate than previous work has found for the US; here, above half the surveyed healthcare workers expressed that they had not yet made a decision on the matter [69, 70]. There have been similar findings of low acceptance rates across the world, including in Ghana (39.3%) [71], Nepal (38.3%) [72], the Democratic Republic of Congo (27.7%) [73], and Egypt (21%) [74], while the research has found rates of 50.2% in Nigeria [75] and 50.52% in Saudi Arabia [76].

A low willingness to take the vaccine could be linked to healthcare workers’ concerns about the vaccines’ efficacy, safety, and side effects, in addition to low vaccine confidence, a lack of knowledge, and mistrust in the vaccines’ effectiveness [63, 77, 78]. Meanwhile, higher vaccine acceptance has been found for individuals with higher socioeconomic status, those who are in direct contact with patients as part of their profession, a perception of risk and fear of the disease, and having previously had an influenza vaccination [33]. Hesitancy among healthcare workers regarding the COVID-19 vaccine could have a two-sided effect: Not only can unvaccinated healthcare workers transmit the virus to their patients, but they are also not able to encourage their vulnerable patients to receive the vaccine [33].

The study is subject to a few limitations. First, we used a cross-sectional survey, which does not allow strong conclusions to be drawn about the possible relationships between the variables; hence, this area would benefit from a longitudinal study. Second, the online self-reporting method used here may have introduced
bias in relation to social acceptability and memory; furthermore, older individuals or those with a lower socioeconomic status may have been excluded due to a lack of Internet access. Hence, the results may not be generalizable. Third, some important concerns may have gone unaccounted for because we used a closed-ended questionnaire. Nonetheless, selection, social desirability, and recall biases are sometimes found in observational methodologies, and these may have been reduced in this study due to the simple random sampling technique. In addition, this study is the first to examine community perceptions in the UAE towards the booster dose, meaning that the findings offer important implications for the makers and planners of health policy, with the aim of vaccinating as many people as possible to end the pandemic.

Conclusions
To the authors’ best knowledge, this study is the first to examine the knowledge, perceptions, and attitudes among the general population in Gulf Cooperation Council countries (GCC) and UAE regarding the COVID-19 vaccine and their willingness to receive the booster dose. We have found that while the participants had generally inadequate knowledge about the booster dose, they did show more positive attitudes towards the vaccination in the context of the UAE. Hence, necessary steps should be taken by the government and public health authorities, in line with the local culture, to increase vaccination acceptance and foster positive attitudes towards the vaccine. A suitable approach to this would be to develop an educational framework that could demonstrate the risks of vaccine avoidance or delay to the general population. Specifically, in order to fight the disease, a transparent educational effort underlining the social benefits of receiving the vaccine would be highly beneficial. Our findings on the public’s knowledge, perceptions and attitudes regarding the booster dose and their refusal to take it can help shape health policies and vaccination campaigns in the UAE. By revealing those factors that are most strongly influencing the willingness to get vaccinated, this study may thus add to the development of a pathway out of the pandemic. Specifically, health authorities should pay more attention to the false information being disseminated across the internet, especially social media. Also, healthcare workers should be trained in vaccinology and virology to make sure that they are able to understand important developments in these fields and convey the findings to their patients.

Acknowledgements
The authors are extremely grateful to the survey participants who took the time to participate in the study. Without their participation and feedback, this study would not have been possible.

Authors’ contributions
AAJ, FEJ and ZB designed the study. MJ, MS, MRAA, and MH responsible for data collection. AAJ, MJ, MH, FE and GH analyzed and interpreted the data. AAJ, SSA, MRAA and FE drafted the manuscript. All authors read and approved the final manuscript.

Funding
The authors received no specific funding for this work.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
The Institutional Ethical Review Committee of AAU approved this study. All individuals who participated in the survey did so voluntarily. The study purpose was outlined on the cover page of the questionnaire, and respondents’ continuing to the subsequent page were assumed to have given their consent. Respondents’ identities were not recorded in any way, and they were assured of their confidentiality.

Consent for publication
Not applicable.

Competing interests
The authors declare that there is no conflict of interest regarding the publication of this article.

Author details
1 Health and Safety Department, Dubai Municipality, Dubai, UAE. 2 School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Gelugor, Pulau Pinang, Malaysia. 3 Pharmacy Department, Emirates Health Services, Dubai, UAE. 4 College of Pharmacy, Al Ain University, Al Ain, UAE. 5 AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, UAE. 6 College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE. 7 Center of Medical and Bio-Allied Health Sciences Research, Ajman University Ajman, Ajman 346, UAE. 8 College of Medicine, University of Sharjah, Sharjah, UAE. 9 Department of Family and Community Medicine and Behavioural Science University of Sharjah, Sharjah, UAE. 10 Edgware Community Hospital Barnet, Enfield and Haringey Mental Health, NHS Trust, Edgware, UK. 11 Department of Pharmacy, University of Huddersfield, Huddersfield HD1 3DH, UK.

Received: 30 December 2021 Accepted: 14 March 2022

References
1. Valencia DN. Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus. 2020;12(3):e7386.
2. Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250(4):271–8.
3. Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clinica chimica acta Int J Clin Chem. 2020;508:254–66.
4. Rahman HS, Aziz MS, Hussein RH, Othman HH, Salih Omer SH, Khalid ES, Abdullahan NA, Amin K, Abdullah R. The transmission modes and sources of COVID-19: a systematic review. Int J Surg Open. 2020;26:125–36.
5. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021;174(1):69–70.
6. Esakkandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaili SM, Baheshe E. A comprehensive review of COVID-19 characteristics. Biol Proc Online. 2020;22:19. https://doi.org/10.1186/s12575-020-00128-2.
7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019
10. Romero Starke K, Peteretz-Haack G, Schubert M, Kämpf D, Schieble A, Hegewald J, Seidler A. The age-related risk of severe outcomes due to COVID-19 infection: a rapid review, meta-analysis, and meta-regression. Int J Environ Res Public Health. 2020;17(16):5974. https://doi.org/10.3390/ijerph17165974.

11. Treskova-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, Koch J, Nygren T, Scholtz S, Schönfeld V, Vigen-Bonnet S, Wichmann O, Harder T. Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. BMC Med. 2021;19(1):212.

12. McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn L, McAllister K, Hatam S, Höhn A, Colombo M, Robertson C, Lone N, Murray J, Butterly E, Petrie J, Scottish Diabetes Research Network Epidemiology Group. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9(2):82–93. https://doi.org/10.1016/S2213-8587(20)30405-8.

13. Preskorn SH. The 5% of the population at high risk for severe COVID-19 infection is identifiable and needs to be taken into account when reopening the economy. J Psychiatr Pract. 2020;26(5):219–27.

14. Pal SM, Othman AA, Sepandi M, Taghdir M, Hosamirudsari H. Determine the vaccine acceptance of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9(2):82–93. https://doi.org/10.1016/S2213-8587(20)30405-8.

15. Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114.

16. Burki T. Booster shots for COVID-19—the debate continues. Lancet Infect Dis. 2021;21(10):1359–60.

17. Del Bello A, Abravanel F, Marion O, Coutar C, Esposito L, Lavayssiere L, Izzo F, Kamar N. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021. doi:10.1111/ajt.16775. Advance online publication.

18. In brief: Third dose of mRNA-based COVID-19 vaccine for immunocompromised persons. The Medical letter on drugs and therapeutics, 2021; 63(1633): 145–146.

19. World Health Organization. Ten threats to global health in 2019. 2019 (cited 2021 Dec 20). https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.

20. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based National Survey. J Multidiscip Healthc. 2020;13:1657–63.

21. Elhadi M, Alsouf I, Alhadi A, Hmeida A, Alshareea E, Dokali M, Abodabos S, Alsidig Q, Abdelkabir M, Ashni A, Shaban A. Knowledge, attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a cross-sectional study. BMC Public Health. 2021;21(1):31–21.

22. Sherman SM, Smith LE, Sim J, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVacCs), a nationally representative cross-sectional survey. Hum Vaccin Immunother. 2020;25:1–10.

23. Malik AA, McFadden SM, Elharaque J, Omar SB. Determinants of COVID-19 vaccine acceptance in the US. EJCLinicalMedicine. 2020;26: 100495. https://doi.org/10.1016/j.eclim.2020.100495.

24. Cerda AA, Garcia LV. Hesitation and refusal factors in individuals’ decision-making processes regarding a coronavirus disease 2019 vaccination. Front Public Health. 2021;9:626852. https://doi.org/10.3389/fpubh.2021.626852.

25. Biswas MR, Alzubaidei MS, Shah U, Abd-Alrazaq AA, Shah Z. A scoring review to find out worldwide COVID-19 vaccine hesitancy and its underlying determinants. Vaccines. 2021;9(1):1243. https://doi.org/10.3390/vaccines9111243.

26. Wysongs CS, Ndawdwe D, Ryan J, et al. Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vaccin Immunother. 2021. https://doi.org/10.1080/21645515.2021.1893062499.

27. Harapan H, Wagner AL, Yufika A, et al. Acceptance of a COVID-19 Vaccine in Southeast Asia: a cross-sectional study in Indonesia. Front Public Health. 2020;8:381.

28. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. 2020;38(49):7789–96. https://doi.org/10.1016/j.vaccine.2020.10.02751.

29. Leng A, Maitland E, Wang S, Nicholas S, Liu R, Wang J. Individual preferences for COVID-19 vaccination in China. Vaccine. 2021;39(2):247–54. https://doi.org/10.1016/j.vaccine.2020.12.00952.

30. Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-BA. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;38(45):7002–6. https://doi.org/10.1016/j.vaccine.2020.09.04153.

31. Gagneux-Brunon A, Detoc M, Bruel S, et al. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. J Hosp Infect. 2021;108:66–73. https://doi.org/10.1016/j.jhin.2021.10.02054.

32. Walkowski MP, Walkowski D. Predictors of COVID-19 vaccination campaign success: lessons learnt from the pandemic so far. A case study from Poland. Vaccines. 2021;9(10):1153. https://doi.org/10.3390/vaccines9101153.

33. Biswas N, Mustapha T, Khubchandani J, Price JH. The nature and extent of COVID-19 vaccination hesitancy in healthcare workers. J Community Health. 2021;46:1244.

34. Adane M, Ademas A, Klos H. Knowledge, attitudes, and perceptions of COVID-19 vaccine and refusal to receive COVID-19 vaccine among healthcare workers in northeastern Ethiopia. BMC Public Health. 2022;22(1):1–4.

35. Shahwan M, Suliman A, Jairou A, Alkhouraj S, Al-Hemaysi SS, Al-Tamimi SK, Godman B, Mothana RA. Prevalence, knowledge and potential determinants of COVID-19 vaccine acceptability among university students in the United Arab Emirates: findings and implications. J Multidiscip Healthc. 2022;15:81.

36. Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review. EClinicalMedicine. 2021;40:101113.

37. Ahmed MH, Siraj SS, Klein J, Ali FY, Kanfe SG. Knowledge and attitude towards second COVID-19 vaccine dose among health professionals working at public health facilities in a low income country. Infect Drug Resist. 2021;14:3125.

38. El-Elimat T, AbuAlSamen MM, Almamoni BA, Al-Sawalha NA, Alali QF. Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan. PLoS ONE. 2021;16(4):e0250555.

39. Lawshe CH. A quantitative approach to content validity. Pers Psychol. 1975;28:563–73.

40. Politz DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal Recommend Res Nurs Health. 2007;30:459–67.

41. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(7):1470–7.

42. Wong MCS, Wong ELY, Huang J, Cheung AWL, Law K, Chong MKC, et al. Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine. 2021;39(7):1148–56.

43. Abdullah AC, NA M, Rosliza AM. Predictors for inadequate knowledge and negative attitude towards childhood immunization among parents in Hulu Langat, Selangor, Malaysia. Malaysian J Public Heal Med. 2018;46:1(1):102–12.

44. Ooi PL, Heng ZY, Boon KY. Factors influencing parents' awareness regarding childhood immunization: findings of cross-sectional study in northeast Penang Island District, Malaysia. Int J Public Heal. 2019;65(3):130–42.

45. Mohamed NA, Solehan HM, Mohd Rani MD, Ithnin M, Che Isahak CI. Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: a web-based survey. PLoS ONE. 2021;16(8):e0256110.
46. Geoghegan S, O’Callaghan KP, Offit PA. Vaccine safety: myths and misinformation. Front Microbiol. 2020;11:372.

47. Banki R, Rahman M, Sikder MT, Rahman QM, Pranta MUR. Knowledge, attitudes, and practices related to the COVID-19 pandemic among Bangladeshi youth: a web-based cross-sectional analysis. J Public Health (Bangkok). 2021. https://doi.org/10.1007/s10389-020-01432-7.

48. Chan EY-Y, Cheng CK-Y, Tam GCH, Huang Z, Lee PY. Willingness of future health professionals to vaccinate against COVID-19: a cross-sectional study of Hong Kong community. Vaccine. 2015;33(8):4737–40.

49. Islam M, Siddique AB, Akter R, Tasnim R, Sujan M, Hossain S, Ward PR, Sikder M. Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh. BMC Public Health. 2021;21(1):1–1.

50. Nor NA, Solehan HM, Mohamed NA, Hasan ZI, Umar NS, Sanip S, et al. Knowledge, attitude and practice (KAP) towards COVID-19 prevention (MCO): an online cross-sectional survey. Int J Res Pharm Sci. 2020;11(2):1458–64.

51. Wang J, Jing R, Lai X, Zhang H, Lu Y, Kroll MD, et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines. 2020;8(3):482.

52. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–8. https://doi.org/10.1038/s41591-020-1124-9.

53. Sallam M, Ababneh D, Eid H, Al-Mahzoum K, Al-Haider A, Taim D, Yaseen A, Ababneh NA, Bakri FG, Mahafzah A. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among Other Arab countries. Vaccines. 2021;9(1):42. https://doi.org/10.3390/vaccines9010042.

54. Maurer J, Uscher-Pines L, Harris KM. Perceived seriousness of seasonal and A(H1N1) influenza, attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter? Prev Med (Baltim). 2010;51:85–7.

55. Islam MS, Kamal AH-M, Kabir A, Southern DL, Khan SH, Hasan SMM, et al. COVID-19 vaccine rumors and conspiracy theories: the need for cognitive inoculation against misinformation to improve vaccine adherence. PLoS ONE. 2021;16(5):e0251605.

56. Barello S, Nania T, Dellafore F, Graffigna G, Caruso R. ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol. 2020;35(8):781–3. https://doi.org/10.1007/s10654-020-00670-z.

57. Kanyike AM, Olum R, Kajjimu J, et al. Acceptance of the coronavirus disease 2019 (COVID-19) vaccine among Ugandan medical students. Trop Med Health. 2021;49(1):37. https://doi.org/10.1186/s12278-021-00331-1.

58. Riad A, Schünemann H, Attia S, et al. COVID-19 Vaccines Safety Tracking (CoVST): a protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines’ side effects. Int J Environ Res Public Health. 2021;18(15):7859. https://doi.org/10.3390/ijerph18157859.

59. Riad A, Pokorná A, Klugarová J, et al. Side effects of mRNA-based COVID-19 vaccines among young adults (18–30 years old): an independent rapid post-marketing study. Pharmaceuticals. 2021;14(10):1049. https://doi.org/10.3390/ph14101049.

60. Jin Q, Raza SH, Youssf M, Zamani U, Siang JMLD. Can communication strategies combat COVID-19 vaccine hesitancy with trade-off between public service messages and public skepticism? Experimental evidence from Pakistan. Vaccines. 2021;9(7):757. https://doi.org/10.3390/vaccines9070757.

61. Wang P-W, Ahorus DK, Lin C-Y, et al. Motivation to have COVID-19 vaccination explained using an extended protection motivation theory among university students in china: the role of information sources. Vaccines. 2021;9(4):380. https://doi.org/10.3390/vaccines9040380.

62. Faasse K, Newby J. Public perceptions of COVID-19 in Australia: perceived risk, knowledge, health-protective behaviors, and vaccine intentions. Psychol. 2020;11:551004.

63. Latafeh L, Al-Ain A, Latafeh I, Ammar K, Al-Hammouri F, Al-Hussaini M. Knowledge, attitudes, and practices of healthcare workers in Jordan towards the COVID-19 vaccination. Vaccines. 2022;10(2):263.

64. Ssemongo P, Ssemongo AE, Heibrum ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS ONE. 2020;15(8):e0238215.